Protein Discovery In The Age Of AI
Twist Bioscience’s high-throughput DNA synthesis platform is enabling AI researchers to compress protein discovery timelines and expand therapeutic possibilities.| Asian Scientist Magazine
Twist Bioscience’s high-throughput DNA synthesis platform is enabling AI researchers to compress protein discovery timelines and expand therapeutic possibilities.| Asian Scientist Magazine
New Jersey’s Department of Environmental Protection (DEP) has filed a lawsuit against Pfizer, Johnson & Johnson, Honeywell and several real estate companies, claiming there is toxic waste on an old pharmaceutical plant site, contaminating the groundwater. The plant, located in Morris Plains, was operational from the 1950s to the 1980s under Warner-Lambert, which Pfizer acquired… The post NJ sues Pfizer and others for water contamination appeared first on Drug Discovery and Development.| Drug Discovery and Development
The pharmaceutical blockbuster model is wobbling. And no single franchise is safe. While king Keytruda, Merck’s stalwart oncology drug, continues to rule the first half of 2025 with $15.2B in sales (Q1 $7.2B, Q2 $8.0B), its U.S. patent expiry in 2028 the single biggest loss of exclusivity event on the horizon. In the U.S., Medicare… The post Top 25 drugs by sales: 2025 H1 appeared first on Drug Discovery and Development.| Drug Discovery and Development
The influence of the pharmaceutical industry on the Food and Drug Administration (FDA) has been recognized with concern for decades across the political spectrum. But the industry's influence on Washington... The post Health Freedom Defense Fund Spotlights Gutted FDA Inspection Requirements for Biological Products and Vaccines appeared first on Health Freedom Defense Fund.| Health Freedom Defense Fund
Bispecific antibodies are a rapidly advancing class of therapeutics, offering a new level of precision in treating diseases like cancer.| Drug Discovery and Development
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
In April 2023, I received a letter from the Ontario government with information about the new biosimilar switching policy. I had until the end of the year to switch from the biologic medication I take to treat my rheumatoid arthritis (RA) to a biosimilar. I did my best to be hopeful and believe it would…| The Seated View
In March 2023, I received a letter from the Ontario government. It informed me that a biosimilar switching policy was now in place. People like me who receive funding from the government to pay for Biologics for rheumatoid arthritis (RA), Crohn’s disease, and other forms of autoimmune disease were given until the end of 2023…| The Seated View
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Learning that a biologic medicine hasn’t worked for you is hard. Being told that you have “failed” that medicine is worse. Let’s change that narrative. You didn’t fail. The medicine failed you.| CreakyJoints Australia
Were you affected by the abatacept (Orencia®) shortage this year? If so, we have great news. The supply situation in Australia has improved and you may be able to return to your previous treatment regime.| CreakyJoints Australia
